Scientists identify cancer ‘kill switch,’ could revolutionize treatments
- Scientist: Activation of "kill switch" could revolutionize cancer treatment
- Doctor: "You get targeted, specific killing of those cells"
- Research doesn't have enough clinical trials, human tests
Testing widget old system
DAVIS, Calif.(NewsNation) — In a remarkable new discovery, scientists at UC Davis in California have identified a “kill switch” that can activate the death of cancer cells — potentially paving the way for new cancer treatment.
The implications of these new findings are immense and could potentially revolutionize cancer treatment.
However, it has not yet been tested on animals or humans but has been proven successful in labs thus far.
Scientists are calling it a potential cancer treatment breakthrough.
“You get targeted, specific killing of those cells that are potentially going to do you harm. Then the healthy cells are left untouched. That is just ideal,” Dr. Jill Waggoner, a family physician, said.
Researchers from the UC Davis Comprehensive Cancer Center claim they’ve located a so-called “kill switch” that can eliminate cancer cells. The researchers published their findings in the Nature journal Cell Death & Differentiation.
“This is a game changer,” Dr. Jogender Tushir-Singh, an associate professor at UC Davis, said.
Tushir-Singh is a senior author of the new cancer study. He explained the combination of immunotherapy along with the activation of this new “kill switch,” could revolutionize how doctors treat cancer.
“Think of it like a boxing game. You can keep boxing a person on the belly, but it will take forever to eliminate an opponent. But if you can make the right punch at the right place, you can really eliminate it,” Tushir-Singh said.
Tushir-Singh said his team found a certain receptor that they believe can send a signal that causes cancer cells to self-destruct.
However, the new research comes with its shortfalls and limitations. There aren’t enough clinical trials. So far, it’s shown to be the most effective in treating liquid cancers, not tumors.
“Liquid cancers are generally those cancers that are blood-borne cancers. So things like leukemia, where the cells are loose and circulating. So, not a solid tumor. Solid tumors are like lung cancers or ovarian cancers,” Waggoner said.
The other major drawback so far for this treatment is that it costs $500,000.
